TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25136746

Group type: EXPERIMENTAL
Intervention: Combined standard‐dosed Solifenacin and Trospium
Number of subjects: 417

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 417
Study: 24993931

Group type: EXPERIMENTAL
Intervention: Self-operated endovaginal telemonitoring (SOET)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Traditional monitoring (non-SOET)
Number of subjects: 121
Study: 21924576

Group type: EXPERIMENTAL
Intervention: Internet-based diabetes self-management program
Number of subjects: 463

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 463
Study: 19573247

Group type: EXPERIMENTAL
Intervention: Individualized walking programme
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Supervised general exercise programme
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 246
Study: 17468819

Group type: EXPERIMENTAL
Intervention: Intravenous antimicrobial prophylaxis alone
Number of subjects: 491

Group type: COMPARATOR
Intervention: Combined oral and intravenous antimicrobial prophylaxis
Number of subjects: 491
Study: 15800157

Group type: EXPERIMENTAL
Intervention: Antidepressant plus olanzapine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antidepressant plus placebo
Number of subjects: 20
Study: 11804772

Group type: EXPERIMENTAL
Intervention: Interactive computerized decision aid
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard audio‐booklet decision aid
Number of subjects: 51
Study: 10690139

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Epidural (EPI) analgesia
Number of subjects: 1008
Study: 8750244

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study: 1742537

Group type: EXPERIMENTAL
Intervention: 3MU of interferon three times a week for six months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Resumption of interferon at the same dosage after relapse
Number of subjects: 66

Group type: COMPARATOR
Intervention: 3MU of interferon for four months
Number of subjects: 66
Study: 7201436

Group type: EXPERIMENTAL
Intervention: Argon laser treatment for pigment epithelial detachments (6 eyes)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Argon laser treatment for subretinal neovascular membranes (7 eyes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group for pigment epithelial detachments (7 eyes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group for subretinal neovascular membranes (6 eyes)
Number of subjects: 26
Study: 30896417

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 235
Study: 28573743

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg as one injection every 4 weeks)
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg as one injection every 2 weeks)
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Ixekizumab (both dosing regimens)
Number of subjects: 2570
Study: 25080876

Group type: EXPERIMENTAL
Intervention: IA clodronate 2 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 80
Study: 23293924

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) imaging
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3D fusion imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: LGE imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cryoablation
Number of subjects: 50
Study: 21070569

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin
Number of subjects: 96
Study: 19459829

Group type: EXPERIMENTAL
Intervention: 10-mg metoclopramide ODT
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional 10-mg metoclopramide tablet
Number of subjects: 41
Study: 17470680

Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with lapatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 0
Study: 15522362

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 454

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 454
Study: 11441770

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marital/couples psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study: 9693891

Group type: EXPERIMENTAL
Intervention: Transnasal gastroscopy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Conventional oral gastroscopy
Number of subjects: 181
Study: 7943066

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (800 ml bolus of normal saline followed by continuous infusion at 180 ml/hr)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 124
Study: 3211167

Group type: EXPERIMENTAL
Intervention: Aminophyllin treatment administered orally for one week
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no aminophyllin treatment)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Aminophyllin treatment continued for at least 6 weeks, followed by monitoring one week after discontinuation
Number of subjects: 33
Study: 30422942

Group type: EXPERIMENTAL
Intervention: Parent-directed tablet computer distraction
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard supportive care
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Parent-directed tablet computer distraction (unrestrained)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard supportive care (unrestrained)
Number of subjects: 77
Study: 31677213

Group type: EXPERIMENTAL
Intervention: Pre-term pre-schoolers
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Pre-schoolers who reported asthma in the first year of life
Number of subjects: 811
Study: 29637918

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 2000IU/day for 6 months
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 112
Study: 28877949

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneous for 5 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intramuscular methylprednisolone 120 mg
Number of subjects: 32
Study: 26591677

Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Leflunomide (LEF)
Number of subjects: 304
Study: 23645012

Group type: EXPERIMENTAL
Intervention: Hemostatic sealant (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thrombin solution (n=10)
Number of subjects: 20
Study: 21311513

Group type: EXPERIMENTAL
Intervention: Strawberry flavoured acidic gum
Number of subjects: 8

Group type: COMPARATOR
Intervention: Peppermint flavoured non-acidic gum
Number of subjects: 8
Study: 19398604

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on the first day and then 75 mg once daily for 3 consecutive days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16188496

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6-MWT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maximal incremental treadmill exercise test with metabolic gas exchange measurements
Number of subjects: 120
Study: 15232812

Group type: EXPERIMENTAL
Intervention: Percutaneous intercostal nerve block using plain bupivacaine 0.375%
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Percutaneous intercostal nerve block using bupivacaine 0.375% in dextran 40
Number of subjects: 52

Group type: COMPARATOR
Intervention: No intercostal blockade (retrospective group)
Number of subjects: 52
Study: 11506755

Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Number of subjects: 107

Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 107
Study: 9229884

Group type: EXPERIMENTAL
Intervention: Postal invitations with user fee ($40-$60 US)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Free influenza vaccination invitation
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control group (vaccinated on their own request, paying usual fee)
Number of subjects: 585
Study: 7955806

Group type: EXPERIMENTAL
Intervention: Prazosin (0.25 to 1.0 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 5
Study: 2701751

Group type: EXPERIMENTAL
Intervention: Dried thyroid gland (Thyroideum‐Polfa)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium salt of L‐thyroxine (L‐T4)
Number of subjects: 20
Study: 30295870

Group type: EXPERIMENTAL
Intervention: Gamma Knife Surgery (GKS)
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Medical management only (as per ARUBA trial)
Number of subjects: 1351
Study: 29147070

Group type: EXPERIMENTAL
Intervention: Psychobiotics oral suspension group (POSG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment group (CTG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary treatment group (DTG)
Number of subjects: 0
Study: 26305617

Group type: EXPERIMENTAL
Intervention: TZD use (Rosiglitazone or Pioglitazone) for 1-2 years
Number of subjects: 6865

Group type: EXPERIMENTAL
Intervention: TZD use (Rosiglitazone or Pioglitazone) for >2 years
Number of subjects: 6865

Group type: EXPERIMENTAL
Intervention: TZD discontinuation for 1-2 years
Number of subjects: 6865

Group type: EXPERIMENTAL
Intervention: TZD discontinuation for >2 years
Number of subjects: 6865

Group type: COMPARATOR
Intervention: TZD use and discontinuation
Number of subjects: 6865
Study: 24289513

Group type: EXPERIMENTAL
Intervention: Early, goal directed, protocolised resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual resuscitation
Number of subjects: 0
Study: 21699951

Group type: EXPERIMENTAL
Intervention: 9 μg HA/strain TIV ID
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: 6 μg HA/strain TIV ID
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: 3 μg HA/strain TIV ID
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: 6 μg HA/strain TIV ID (50-64 years subgroup)
Number of subjects: 1592

Group type: COMPARATOR
Intervention: Standard 15 μg HA/strain TIV IM
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: ID administration
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: TIV ID administration experience
Number of subjects: 1592
Study: 18298480

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Combination of BNP and pneumonia severity index (PSI)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 302
Study: 17176529

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 15363481

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 11020746

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 50
Study: 8829417

Group type: EXPERIMENTAL
Intervention: Lidocaine 70 mg in 7.5% glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meperidine 60 mg in saline
Number of subjects: 20
Study: 1640755

Group type: EXPERIMENTAL
Intervention: Random CO2 inhalation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Random work rate forcing
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Simultaneous CO2 inhalation and exercise
Number of subjects: 5
Study: 6340511

Group type: EXPERIMENTAL
Intervention: Single MCA injection
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single MCA injection after uterine lavage
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Two MCA injections 1 month apart
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Radiopaque MCA
Number of subjects: 23
Study: 30132724

Group type: EXPERIMENTAL
Intervention: Yoga Education Program (YEP)
Number of subjects: 792
Study: 31488785

Group type: EXPERIMENTAL
Intervention: Religious content of delusions and hallucinations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diversity of religious and spiritual themes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Occurrence of contact with God and other religious figures
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Number of 'visions'
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Religious content
Number of subjects: 100
Study: 26873658

Group type: EXPERIMENTAL
Intervention: Routine care and silicone foam border dressing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study: 26091383

Group type: EXPERIMENTAL
Intervention: Subantimicrobial, modified-release (MR) Doxycycline 40 mg
Number of subjects: 662

Group type: COMPARATOR
Intervention: Doxycycline 100 mg
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study: 23559535

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (70.6% of patients attended)
Number of subjects: 3560
Study: 21815708

Group type: EXPERIMENTAL
Intervention: Pravastatin (10-20 mg/day)
Number of subjects: 7832
Study: 19531281

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 10, 30 or 60 ml for 12 weeks
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 60 ml
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 16835825

Group type: EXPERIMENTAL
Intervention: U/DD (stepping up for 1 second and stepping down for 2 seconds)
Number of subjects: 20

Group type: COMPARATOR
Intervention: U/D (stepping up and down in the same rhythm of one second each)
Number of subjects: 20
Study: 15390050

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25-4.0 mg/day)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 11436681

Group type: EXPERIMENTAL
Intervention: Patients with alopecia areata (AA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 18
Study: 9492089

Group type: EXPERIMENTAL
Intervention: Typical JNCL (homozygous for the common 1.02 kb deletion)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Typical JNCL (heterozygous for the common 1.02 kb deletion)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Atypical JNCL (heterozygous for the common 1.02 kb deletion)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Atypical JNCL (no common 1.02 kb deletion)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Atypical JNCL (deficient PPT levels)
Number of subjects: 191
Study: 8058422

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ; 5 mg/kg/dose Q6h for 36 hr)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aminophylline (AMINO; 8 mg/kg bolus then 2.5 mg/kg Q12h for 36 hr)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aminophylline (AMINO)
Number of subjects: 14
Study: 2680474

Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diet-Exercise (DE)
Number of subjects: 12
Study: 31661578

Group type: EXPERIMENTAL
Intervention: High-frequency TENS
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS
Number of subjects: 75

Group type: COMPARATOR
Intervention: Transient Placebo TENS
Number of subjects: 75
Study: 31002710

Group type: EXPERIMENTAL
Intervention: Event-based PM tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity-based PM tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reward condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-reward condition
Number of subjects: 0
Study: 27999118

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OCs)
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: Progestin
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Spontaneous menses
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: Progestin-induced menses
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OCs) induced menses
Number of subjects: 1508
Study: 26711755

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 8 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 10 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg/day to 10 mg/kg/day
Number of subjects: 0
Study: 24004650

Group type: EXPERIMENTAL
Intervention: Continuous Short Wave Diathermy (CSWD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pulsed Short Wave Diathermy (PSWD)
Number of subjects: 24
Study: 22164808

Group type: EXPERIMENTAL
Intervention: Equine-assisted activities (therapeutic riding treatment)
Number of subjects: 24
Study: 19386439

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 19
Study: 16710114

Group type: EXPERIMENTAL
Intervention: 20 mg dronabinol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 16.5 mg D9‐tétrahydrocannabinol (THC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 45.7 mg THC as a cannabis milk decoction
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cannabis Influence Factor (CIF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: THC, 11‐OH‐THC and THC‐COOH blood concentrations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Driving simulator tests
Number of subjects: 8
Study: 12705062

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2 selective NSAIDs (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastro-protective agents (proton pump inhibitors or misoprostol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0
Study: 10888949

Group type: EXPERIMENTAL
Intervention: Lumbar discography
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control groups (patients with somatization disorder without discography and patients with low back pain observed for 1 year after discography without surgery)
Number of subjects: 26
Study: 9082601

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (10-30 mg 4 times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1431010

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily, increased to 30 mg after 1 week)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Amitriptyline (50 mg daily, increased to 100 mg after 1 week)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 101
Study: 3904312

Group type: EXPERIMENTAL
Intervention: 5 mg bromocriptine per os
Number of subjects: 20

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 20
Study: 31395229

Group type: EXPERIMENTAL
Intervention: Intra-umbilical vein injection of carbetocin (1 mL containing 100 μg carbetocin diluted in 20 mL normal saline 0.9%)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intra-umbilical vein injection of oxytocin (20 IU diluted in 20 mL normal saline 0.9%)
Number of subjects: 200
Study: 28895655

Group type: EXPERIMENTAL
Intervention: Insulin glargine (titrated doses targeting fasting normoglycaemia)
Number of subjects: 0
Study: 27101881

Group type: EXPERIMENTAL
Intervention: Intervention group (schools with trained teachers)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Control group (schools without trained teachers)
Number of subjects: 464
Study: 24910271

Group type: EXPERIMENTAL
Intervention: Deep bolus injection into the mid‐ to lateral cheek
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local mid‐ to deep dermal injection into the nasolabial fold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both deep injection into the mid‐ to lateral cheek and local mid‐ to deep dermal injection into the nasolabial fold
Number of subjects: 0
Study: 22399125

Group type: EXPERIMENTAL
Intervention: Bupivacaine combined with low dose fentanyl (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine combined with low dose fentanyl (Group L)
Number of subjects: 60
Study: 20070556

Group type: EXPERIMENTAL
Intervention: Immediate feedback (IFB) of HbA1c results via point‐of‐care fingerstick testing
Number of subjects: 215

Group type: COMPARATOR
Intervention: Conventional feedback of HbA1c results via venipuncture and laboratory assessment
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Immediate feedback (IFB) of HbA1c results
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Fingersticks (IFB)
Number of subjects: 215
Study: 18184902

Group type: EXPERIMENTAL
Intervention: Soy protein diet (0.8 g protein/kg body weight; 35% animal proteins, 35% textured soy protein, 30% vegetable proteins)
Number of subjects: 41
Study: 16884968

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study: 12478070

Group type: EXPERIMENTAL
Intervention: Thai-CDC regimen
Number of subjects: 139

Group type: COMPARATOR
Intervention: HIVNET-012 regimen
Number of subjects: 139
Study: 10447133

Group type: EXPERIMENTAL
Intervention: Health education according to WHO's recommendations on breastfeeding
Number of subjects: 1250
Study: 7586939

Group type: EXPERIMENTAL
Intervention: Lys(B28), Pro(B29)-human insulin (lispro)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 0
Study: 2179176

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g suspension, 4 times a day orally)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard oral hygiene (control group)
Number of subjects: 45
Study: 222741

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 10